Eight outcome-specific wellness systems — oral formulas and topical companions, co-designed around peptide science, GMP-manufactured, and lawful in Canada and the United States by construction. No grey market. No fine-print fictions.
Legality is our design language. Every peptide we discuss — on this site, in our papers, in our feed — is published with its current regulatory status in Canada and the US. If a compound isn't lawful, we say so, and we don't sell it.
Not ingredients — systems. Each subscription pairs an oral formula (and, where the tissue can be reached from the surface, a topical companion) around one outcome, at ratios our formulation team will defend line by line.
Collagen synthesis — like every process our systems target — is multi-step. Supply one step and the result is limited by whichever step you skipped. Our formulas supply all three, at defined ratios. The ratios are what we patent.
A peptide or peptide-adjacent active that instructs the target tissue — collagen fragments that tell fibroblasts to build, topical signal peptides at the concentrations the studies actually used.
The free-form amino acids the tissue needs to act on that instruction. A signal without material is a work order sent to an empty warehouse.
The vitamins and minerals the enzymatic steps require. Small quantities, non-negotiable chemistry.
A $100M+/year economy sells "research chemicals" to human users with no approval, no quality control, and no accountability. We exist to serve that demand the other way — with everything the grey market cannot offer.
The peptide category is drowning in hype and starving for straight answers. We publish ours openly — take them, cite them, share them. Authority is our marketing budget.
Drug, cosmetic, natural health product, supplement — how one molecule can live four legal lives, and how to read the difference.
Download PDF →The verified timeline of the 2026 reclassification — what the PCAC actually voted, what remains undecided, and what it means for consumers.
Download PDF →What randomised trials actually show for skin, joints, and bone density — and what dose and duration they showed it at.
Download PDF →Fifty years of copper-peptide science, what's lawful (topical) versus what isn't (injectable), and how to read a label.
Download PDF →What people are actually buying, what they're taking it for, and what the purity data says. Market intelligence, published.
Download PDF →The $4.2B capacity race, the licence stack, and why building a compliant facility takes years, not quarters.
Download PDF →Public domain means public domain. Our white papers are released without copyright restriction. Journalists, clinicians, educators, competitors: use them. Every accurate sentence in circulation about peptide legality makes our market bigger and the grey market smaller.
Regulatory moves, published science, and industry signals — logged as they happen, each entry tagged and dated. This is the feed we run our own regulatory watch on. Now it's yours too.
One email. Every regulatory move, status-stamped. No hype, no cures, no spam.
Our sales structure separates capital from selling — permanently. Nobody buys the right to earn. Nobody earns for recruiting. Commission is paid on verified customer sales, full stop.
25 territory seats. A preferred-share investment — permanent, never performance-contingent, never clawed back.
Fully separate from selling. Founders anchor territories; their shares don't depend on anyone's sales, and no sale depends on their shares.
Subject to counsel clearance — agreements are signed only after securities and consumer-protection review completes. That's a feature.
Costs nothing to join. No kit, no inventory requirement, no fee — ever.
Paid on real sales only. Agents 15% · Sub-Distributors 5% · Distributors 10% — on verified customer subscriptions and every renewal, never on recruiting.
Trained and certified. Every partner passes product and claims certification before their first sale. One approved claims library, no freelancing.
Be first for the Phase 1 systems, the white papers as they publish, and the Peptide Report. Tell us what you're here for and we'll keep it relevant.